GASTROClear
GASTROClear™
GASTROClear™ is a blood-based molecular diagnostic test for gastric cancer developed by Mirxes, a Singapore-headquartered biotechnology company. It was the world's first serum gastric cancer molecular diagnostic assay to receive regulatory approval, clearing in Singapore in 2019 . The test detects 12 miRNA biomarkers and is designed as a non-invasive early-screening alternative to endoscopy, which remains dependent on physician experience and has seen limited adoption in mass screening despite its theoretical accuracy . As of 2024, it remained the only approved blood-based gastric cancer early-screening product globally, marking what Mirxes described as the transition of miRNA science from Nobel-discovery stage into clinical application . By May 2025, GASTROClear™ was Mirxes's sole core commercial product alongside two other marketed tests, LUNGClear™ and Fortitude™, as the company prepared for its Hong Kong IPO .
AI-generated — may contain errors, please verify.
Coverage
Congratulations to Mirxes on its successful listing on the Hong Kong Stock Exchange's Main Board — Gaorong Ventures was its earliest institutional investor.
A leading provider of molecular cancer screening products and services.
From Nobel Discovery to Clinical Application: Mirxes Is Transforming Cancer Early Screening with miRNA Technology | Gaorong Ventures
Focused on miRNA technology development, pioneering early cancer screening worldwide.
"Tiny but Mighty" miRNA: How Cancer Can Be Caught at Its Earliest Stage | Gaorong Ventures "Future"
By applying microRNA to early cancer screening, we can transform cancer from a terminal illness into a chronic disease that can be intercepted at an early stage.
Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
